Feinstein Institute researchers show a genetic overlap in schizophrenia and cognitive ability

December 17, 2013

MANHASSET, NY - Investigators at The Feinstein Institute for Medical Research have discovered for the first time, direct evidence of a genetic overlap between schizophrenia and general cognitive ability. The findings are published online in Molecular Psychiatry.

Schizophrenia is a chronic, severe and disabling brain disorder that affects approximately 2.2 million Americans each year. It is characterized by a significant reduction in general cognitive abilities, so that many patients struggle with completing school, holding jobs and achieving their full potential. Previous studies have indicated subtle cognitive abnormalities in undiagnosed and unmedicated relatives of patients who live with schizophrenia, which suggests the possibility of genetic overlap between risk for schizophrenia and cognitive traits. These previous studies, however, did not test this overlap on the molecular level.

Anil Malhotra, MD, director of psychiatry research at Zucker Hillside Hospital and an investigator at the Feinstein Institute, and his colleague Todd Lencz, PhD, associate investigator at the Zucker Hillside Hospital and the Feinstein Institute, conducted the first molecular genetic test to determine if genetic markers of reduced cognitive ability were also genetic markers of increased schizophrenia risk. Specifically, they conducted a large-scale, meta-analysis, genome-wide association study (GWAS) of samples from 5,000 subjects provided by the Cognitive Genomics consorTium (COGENT). COGENT, which was founded and is led by Dr. Malhotra, is an international consortium of nine teams of researchers across seven countries. Through their analysis, they confirmed that patients who suffered from schizophrenia also had lessened cognitive ability. This is the first direct evidence for genetic overlap between schizophrenia risk genes and genes that regulate general cognitive ability, such as memory, attention, and language abilities. The results provide molecular confirmation of this genetic overlap and additional insight into how schizophrenia develops and progresses.

"This research leads us to a deeper understanding of how schizophrenia affects the brain at the molecular level," said Dr. Lencz. "Our studies are designed to provide clues to the development of new treatments to improve the lives of our patients."
-end-
About The Feinstein Institute for Medical Research

Headquartered in Manhasset, NY, The Feinstein Institute for Medical Research is home to international scientific leaders in many areas including Parkinson's disease, Alzheimer's disease, psychiatric disorders, rheumatoid arthritis, lupus, sepsis, human genetics, pulmonary hypertension, leukemia, neuroimmunology, and medicinal chemistry. The Feinstein Institute, part of the North Shore-LIJ Health System, ranks in the top 6th percentile of all National Institutes of Health grants awarded to research centers. For more information, visit http://www.FeinsteinInstitute.org.

Northwell Health

Related Schizophrenia Articles from Brightsurf:

Schizophrenia: When the thalamus misleads the ear
Scientists at the University of Geneva (UNIGE) and the Synapsy National Centre of Competence in Research (NCCR) have succeeded in linking the onset of auditory hallucinations - one of the most common symptoms of schizophrenia - with the abnormal development of certain substructures of a region deep in the brain called the thalamus.

Unlocking schizophrenia
New research, led by Prof. LIU Bing and Prof. JIANG Tianzi from the Institute of Automation of the Chinese Academy of Sciences and their collaborators have recently developed a novel imaging marker that may help in the personalized medicine of psychiatric disorders.

Researchers discover second type of schizophrenia
In a study of more than 300 patients from three continents, over one third had brains that looked similar to healthy people.

New clues into the genetic origins of schizophrenia
The first genetic analysis of schizophrenia in an ancestral African population, the South African Xhosa, appears in the Jan.

Dietary supplement may help with schizophrenia
A dietary supplement, sarcosine, may help with schizophrenia as part of a holistic approach complementing antipsychotic medication, according to a UCL researcher.

Schizophrenia: Adolescence is the game-changer
Schizophrenia may be related to the deletion syndrome. However, not everyone who has the syndrome necessarily develops psychotic symptoms.

Study suggests overdiagnosis of schizophrenia
In a small study of patients referred to the Johns Hopkins Early Psychosis Intervention Clinic (EPIC), Johns Hopkins Medicine researchers report that about half the people referred to the clinic with a schizophrenia diagnosis didn't actually have schizophrenia.

The ways of wisdom in schizophrenia
Researchers at UC San Diego School of Medicine report that persons with schizophrenia scored lower on a wisdom assessment than non-psychiatric comparison participants, but that there was considerable variability in levels of wisdom, and those with higher scores displayed fewer psychotic symptoms.

Recognizing the uniqueness of different individuals with schizophrenia
Individuals diagnosed with schizophrenia differ greatly from one another. Researchers from Radboud university medical center, along with colleagues from England and Norway, have demonstrated that very few identical brain differences are shared amongst different patients.

Resynchronizing neurons to erase schizophrenia
Today, a decisive step in understanding schizophrenia has been taken.

Read More: Schizophrenia News and Schizophrenia Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.